



# Erratum

**Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980**

<https://doi.org/10.2337/dc17-er06d>

In the Research Design and Methods section of the abstract of the above-mentioned article, the value of “<5.6 mmol/mol” should read “<5.6 mmol/L.”

The online issue has been corrected to reflect this change.

*Vanita R. Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, and Richard M. Bergenstal, on behalf of the LixiLan-L Trial Investigators*